Paris, France, Monday, May 11, 2026, 6:30 pm CEST – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the publication of a Matching Adjusted Indirect Comparison (MAIC) of outcomes from the clinical trials of GS010/LUMEVOQ®, the Company’s gene therapy investigational product for the treatment of ND4-LHON (Leber Hereditary Optic Neuropathy),[1] and idebenone, the only approved treatment for LHON. The study was published in the April 2026 issue of the journal British Journal of Ophthalmology.

The full article, named “Efficacy of lenadogene nolparvovec gene therapy versus idebenone in Leber hereditary optic neuropathy due to the m.11778G>A MT- ND4 variant: two matching adjusted indirect comparisons“, is available online on this link.

[1] GS010/LUMEVOQ® has not, to date, received marketing authorization in any country and is therefore not available commercially.

Contacts